image credit: Pexels

UCT and partners develop and validate new TB blood test

Researchers from the University of Cape Town’s (UCT) South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research – Seattle, US, and a consortium of collaborators have developed and validated a new test for tuberculosis (TB).

Named RISK6, the new blood-based test can identify healthy individuals who are at risk of developing TB. It can also identify people with subclinical or clinical disease and help understand how well a patient would respond to the treatment.

The test, which can be applied to capillary blood collected by finger prick, is currently validated in seven cohorts across two continents.